Jupiter Neurosciences licenses U.S. rights to ALA-002 in deal worth up to $100 million
The agreement with PharmAla adds an FDA-designated Novel Chemical Entity to Jupiter’s Phase II Parkinson’s disease pipeline and gives the company perpetual exclusive U.S. rights.